UNSPSC 51152054: Decamethonium bromide

This classification denotes a muscle relaxant with the molecular formula C16H38N2.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 55C6RK944K, chemically known as 1,10-decanediaminium, n,n,n,n,n,n-hexamethyl-, monobromide but more generally known as decamethonium bromide, which bears US NIH Compound Identifier 2968. European Medicines Agency schedules Decamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06930MIG.

UNSPSC 51152054 Decamethonium bromide is a Commodity code representing a specific pharmaceutical agent; however, the recent state and local opportunities tagged under this code show minimal alignment with the code's nominal scope. The solicitations posted under this code focus on naloxone procurement and pharmacy benefit program initiatives rather than decamethonium bromide specifically. State and local governments are using this code to acquire emergency medical supplies, drug deactivation systems, and pharmacy services — suggesting either a data-tagging misalignment or a broader pharmaceutical-supply categorization in some jurisdictions' procurement systems. Issuing bodies include county health departments and state health agencies (Seminole County, Florida and the Texas Health and Human Services Commission). The work involves competitive bidding for naloxone units and safe drug deactivation systems for community health initiatives, as well as exploratory procurement (RFI) for direct-to-manufacturer pharmacy programs serving state employee and retiree health plans.

Recent activity is limited to two opportunities spanning Florida and Texas. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford; the IFB response deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct contracting relationships between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The mismatch between the code's chemical-agent name and the actual solicitation scope suggests that decamethonium bromide shows little relevant recent activity under its nominal classification in state and local procurement.